Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
100 participants
INTERVENTIONAL
2022-06-15
2023-02-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Statin and Beta Blocker Use in Patients with Decompensated Cirrhosis
NCT06764966
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
NCT00375349
Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
NCT01987310
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
NCT05364684
Different Doses of ZED1227 vs. Placebo in NAFLD
NCT05305599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PLACEBO
placebo formula
Placebo
placebo arm
statin
atorvastatin tablets
Atorvastatin 20mg
active arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin 20mg
active arm
Placebo
placebo arm
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Khadija Ahmed Mhrose Glal
Assistant lecturer of clinical pharmacy- Clinical pharmacy department- Faculty of pharmacy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
khadija glal
Role: PRINCIPAL_INVESTIGATOR
assistant lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Statin and iver cirrhosis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.